Subtopic Deep Dive

Arginine Deprivation Therapy
Research Guide

What is Arginine Deprivation Therapy?

Arginine Deprivation Therapy (ADT) uses recombinant human arginase or pegylated arginine deiminase (ADI-PEG20) to deplete systemic arginine, exploiting ASS1 deficiency in cancers like melanoma and hepatocellular carcinoma.

ADT targets tumors auxotrophic for arginine due to low argininosuccinate synthetase (ASS1) expression. Key studies show ASS1 deficiency in 60-90% of melanomas and HCC (Dillon et al., 2004, 330 citations). Clinical trials with ADI-PEG20 demonstrate tumor regression in ASS1-low cancers (Delage et al., 2010, 422 citations).

Curated Papers

Key Challenges

Why It Matters

ADT provides precision therapy for ASS1-deficient malignancies, inducing autophagy and caspase-independent apoptosis in prostate cancer (Kim et al., 2009, 325 citations). It overcomes chemoresistance in cancers with poor prognosis, as arginine supports polyamine synthesis and tumor growth (Delage et al., 2010). Combination with immunotherapy addresses myeloid-derived suppressor cell arginase activity suppressing T-cell responses (Grzywa et al., 2020, 371 citations; Rodríguez et al., 2017, 279 citations).

Key Research Challenges

Resistance via ASS1 Upregulation

Tumors adapt to arginine deprivation by restoring ASS1 expression, limiting ADT efficacy (Delage et al., 2010). This metabolic rewiring sustains polyamine production essential for proliferation (Soda, 2011, 278 citations). Combination therapies are needed to block compensatory pathways.

Myeloid Cell Arginine Catabolism

Arginase from myeloid cells depletes arginine, impairing T-cell immunity and promoting tumor escape (Grzywa et al., 2020, 371 citations). ADT must balance tumor killing with immune preservation (Rodríguez et al., 2017, 279 citations). Strategies to inhibit myeloid arginase enhance responses.

ASS1 Deficiency Heterogeneity

Variable ASS1 loss across cancers complicates patient selection (Dillon et al., 2004, 330 citations). TP53 mutations correlate with ASS1 silencing, but clinical biomarkers remain imprecise (Robles and Harris, 2009, 370 citations). Reliable stratification assays are required.

Essential Papers

Bacteria-cancer interactions: bacteria-based cancer therapy

Mai T. Duong, Yeshan Qin, Sung-Hwan You et al. · 2019 · Experimental & Molecular Medicine · 465 citations

Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer

Barbara Delage, Dean A. Fennell, Linda Nicholson et al. · 2010 · International Journal of Cancer · 422 citations

Abstract Arginine, a semi‐essential amino acid in humans, is critical for the growth of human cancers, particularly those marked by de novo chemoresistance and a poor clinical outcome. In addition ...

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

Xiaohua Chen, Taotao Zhang, Wei Su et al. · 2022 · Cell Death and Disease · 385 citations

Myeloid Cell-Derived Arginase in Cancer Immune Response

Tomasz M. Grzywa, Anna Sosnowska, Paweł Matryba et al. · 2020 · Frontiers in Immunology · 371 citations

Amino acid metabolism is a critical regulator of the immune response, and its modulating becomes a promising approach in various forms of immunotherapy. Insufficient concentrations of essential ami...

Clinical Outcomes and Correlates of TP53 Mutations and Cancer

Ana I. Robles, Curtis C. Harris · 2009 · Cold Spring Harbor Perspectives in Biology · 370 citations

The initial observation that p53 accumulation might serve as a surrogate biomarker for TP53 mutation has been the cornerstone for vast translational efforts aimed at validating its clinical use for...

Incidence and distribution of argininosuccinate synthetase deficiency in human cancers

Brian J. Dillon, Víctor G. Prieto, Steven A. Curley et al. · 2004 · Cancer · 330 citations

Abstract BACKGROUND Argininosuccinate synthetase (ASS) was the first of two enzymes to convert citrulline to arginine. This pathway allowed cells to synthesize arginine from citrulline, making this...

Arginine Deiminase as a Novel Therapy for Prostate Cancer Induces Autophagy and Caspase-Independent Apoptosis

Randie H. Kim, Jodi M. Coates, Tawnya L. Bowles et al. · 2009 · Cancer Research · 325 citations

Abstract Arginine deprivation as an anticancer therapy has historically been met with limited success. The development of pegylated arginine deiminase (ADI-PEG20) has renewed interest in arginine d...

Reading Guide

Foundational Papers

Start with Delage et al. (2010, 422 citations) for arginine auxotrophy mechanism, Dillon et al. (2004, 330 citations) for ASS1 distribution across cancers, and Kim et al. (2009, 325 citations) for ADI-PEG20 preclinical effects.

Recent Advances

Grzywa et al. (2020, 371 citations) on myeloid arginase in immunity; Rodríguez et al. (2017, 279 citations) on arginine metabolism shaping adaptive responses.

Core Methods

ASS1 IHC for auxotrophy screening (Dillon et al., 2004); pegylated ADI-PEG20 for sustained depletion (Kim et al., 2009); arginase activity assays in myeloid cells (Grzywa et al., 2020).

How PapersFlow Helps You Research Arginine Deprivation Therapy

Discover & Search

Research Agent uses searchPapers('arginine deprivation therapy ASS1 deficient cancer') to retrieve Delage et al. (2010, 422 citations), then citationGraph to map 500+ citing works on resistance mechanisms, and findSimilarPapers to uncover ASS1 profiling in unstudied cancers.

Analyze & Verify

Analysis Agent applies readPaperContent on Dillon et al. (2004) to extract ASS1 incidence data across 100+ tumors, verifyResponse with CoVe to validate 65% melanoma ASS1-negativity against claims, and runPythonAnalysis for statistical meta-analysis of survival correlations using GRADE for evidence grading.

Synthesize & Write

Synthesis Agent detects gaps in ADT-immunotherapy combos via contradiction flagging between Grzywa et al. (2020) and Kim et al. (2009), while Writing Agent uses latexEditText to draft reviews, latexSyncCitations for 20+ refs, and latexCompile for publication-ready manuscripts with exportMermaid for ASS1 pathway diagrams.

Use Cases

"Analyze ASS1 expression correlations with TP53 mutations in melanoma from key papers"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas correlation matrix on extracted data from Robles & Harris 2009 + Dillon 2004) → matplotlib survival plots output.

"Draft LaTeX review on ADI-PEG20 clinical trials and resistance"

Synthesis Agent → gap detection on Delage 2010 + Kim 2009 → Writing Agent → latexEditText + latexSyncCitations + latexCompile → camera-ready PDF with ASS1 metabolic diagram.

"Find code for modeling arginine depletion in ASS1-deficient tumors"

Research Agent → paperExtractUrls from Delage 2010 citers → Code Discovery → paperFindGithubRepo → githubRepoInspect → validated simulation scripts for metabolic flux analysis.

Automated Workflows

Deep Research workflow conducts systematic review of 50+ ASS1/ADT papers, chaining searchPapers → citationGraph → GRADE-graded report on therapy efficacy. DeepScan applies 7-step analysis with CoVe checkpoints to verify claims in Grzywa et al. (2020) myeloid arginase data. Theorizer generates hypotheses on ADT-p53 interactions from Robles & Harris (2009).

Try Doxa for Arginine Deprivation Therapy Research

Frequently Asked Questions

What defines Arginine Deprivation Therapy?

ADT depletes plasma arginine using ADI-PEG20 or recombinant arginase, killing ASS1-deficient tumors unable to synthesize arginine (Delage et al., 2010).

What are main methods in ADT?

Pegylated arginine deiminase (ADI-PEG20) converts arginine to citrulline; recombinant human arginase hydrolyzes arginine. ASS1 expression assays stratify patients (Dillon et al., 2004; Kim et al., 2009).

What are key papers on ADT?

Delage et al. (2010, 422 citations) reviews arginine auxotrophy; Dillon et al. (2004, 330 citations) maps ASS1 deficiency; Kim et al. (2009, 325 citations) shows autophagy in prostate cancer.

What are open problems in ADT?

Resistance via ASS1 restoration and myeloid arginase immune suppression persist (Delage et al., 2010; Grzywa et al., 2020). Optimal combos with immunotherapy need trials.